微芯生物
(688321)
| 流通市值：69.20亿 | | | 总市值：69.20亿 |
| 流通股本：4.08亿 | | | 总股本：4.08亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 481,115,043.66 | 302,160,509.05 | 130,604,180.46 | 523,710,192.86 |
| 营业收入 | 481,115,043.66 | 302,160,509.05 | 130,604,180.46 | 523,710,192.86 |
| 二、营业总成本 | 519,910,892.74 | 336,896,673 | 148,782,922.18 | 719,282,373.12 |
| 营业成本 | 59,774,529.51 | 36,516,344.47 | 14,856,237.77 | 56,968,750.82 |
| 税金及附加 | 6,242,934.33 | 4,040,633.18 | 1,955,386.02 | 7,924,626.93 |
| 销售费用 | 236,830,428.49 | 149,709,739.04 | 55,974,005.61 | 284,361,232.88 |
| 管理费用 | 55,554,857.19 | 36,692,834.36 | 18,824,080.47 | 83,544,095.86 |
| 研发费用 | 147,574,384.7 | 102,214,756.98 | 52,501,249.7 | 270,445,270.06 |
| 财务费用 | 13,933,758.52 | 7,722,364.97 | 4,671,962.61 | 16,038,396.57 |
| 其中:利息费用 | 25,616,405.52 | 16,654,415.24 | 8,327,951.15 | 34,736,392.92 |
| 其中:利息收入 | -13,150,188.74 | 8,200,512.44 | 3,571,913.96 | 16,771,264.36 |
| 加:公允价值变动收益 | 85,095.89 | 810,369.87 | 126,493.15 | 835,120.26 |
| 加:投资收益 | -15,060,898.93 | -10,911,857.69 | -4,749,304.41 | 281,193,634.69 |
| 资产处置收益 | 234.5 | 234.5 | 234.5 | - |
| 信用减值损失(新) | 3,167,484.13 | 2,301,758.3 | 1,781,100.29 | -4,333,015.18 |
| 其他收益 | 5,706,052.92 | 5,188,279.82 | 3,355,129.71 | 14,948,216.19 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -44,897,880.57 | -37,347,379.15 | -17,665,088.48 | 97,071,775.7 |
| 加:营业外收入 | 641,925.75 | 610,884.96 | 610,883.68 | 575,428.91 |
| 减:营业外支出 | 634,561.47 | 309,293.83 | 65,137.28 | 628,316.07 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -44,890,516.29 | -37,045,788.02 | -17,119,342.08 | 97,018,888.54 |
| 减:所得税费用 | 6,194,423.54 | 3,960,610.89 | 1,185,303.45 | 47,831,379.45 |
| 六、净利润 | -51,084,939.83 | -41,006,398.91 | -18,304,645.53 | 49,187,509.09 |
| 持续经营净利润 | -51,084,939.83 | -41,006,398.91 | -18,304,645.53 | 49,187,509.09 |
| 归属于母公司股东的净利润 | -51,084,939.83 | -41,006,398.91 | -18,304,645.53 | 88,838,537.36 |
| 少数股东损益 | - | - | - | -39,651,028.27 |
| (一)基本每股收益 | -0.13 | -0.1 | -0.04 | 0.22 |
| (二)稀释每股收益 | -0.13 | -0.1 | -0.04 | 0.22 |
| 八、其他综合收益 | -503,438.33 | 368,462.32 | 112,699.58 | 1,068,982.28 |
| 归属于母公司股东的其他综合收益 | -503,438.33 | 368,462.32 | 112,699.58 | 1,068,982.28 |
| 九、综合收益总额 | -51,588,378.16 | -40,637,936.59 | -18,191,945.95 | 50,256,491.37 |
| 归属于母公司股东的综合收益总额 | -51,588,378.16 | -40,637,936.59 | -18,191,945.95 | 89,907,519.64 |
| 归属于少数股东的综合收益总额 | - | - | - | -39,651,028.27 |
| 公告日期 | 2024-10-31 | 2024-08-16 | 2024-04-29 | 2024-03-30 |
| 审计意见(境内) | | | | 标准无保留意见 |